# Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil

> **NCT04993209** · PHASE1 · COMPLETED · sponsor: **Butantan Institute** · enrollment: 320 (actual)

## Conditions studied

- Coronavirus Infections
- Healthy

## Interventions

- **BIOLOGICAL:** NDV-HXP-S 1μg
- **BIOLOGICAL:** NDV-HXP-S 3μg
- **BIOLOGICAL:** NDV-HXP-S 10μg
- **OTHER:** Adsorbed inactivated COVID-19 vaccine (CoronaVac)

## Key facts

- **NCT ID:** NCT04993209
- **Lead sponsor:** Butantan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-09
- **Primary completion:** 2021-12-10
- **Final completion:** 2022-11-04
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993209, "Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04993209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*